-
10:16:59 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

RDY Stock News

10/14/21 8:00 AM
Nasdaq, NYSE : EXEL, RDY
clinical trial
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
Exelixis, Inc. and Aurigene Discovery Technologies Limited today announced that Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 signaling pathway, which promotes lymphocyte survival and proliferation. XL114 is the second...
RHEA-AI
very positive
10/05/21 8:45 AM
Nasdaq, NYSE : ADTX, RDY
acquisitioncovid-19
Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada
Aditxt, Inc., a biotech innovation company with a mission to improve the health of the immune system, today announced it has entered into a transaction agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary of AiPharma Global Holdings LLC which is to own all of the assets of AiPharma Global, a company focused on discovering,...
RHEA-AI
positive
09/07/21 7:30 AM
Nasdaq, NYSE : CTXR, RDY
acquisitionclinical trial
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE:
RHEA-AI
very positive
09/04/21 1:11 AM
NYSE : RDY
Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
Dr. Reddy’ s Laboratories Ltd., announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. pursuant to which it sold all of its rights to E7777 and certain related assets. Reddy’ s will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40...
RHEA-AI
very positive
09/02/21 12:12 AM
NYSE : RDY
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
Dr. Reddy’ s Laboratories Ltd. today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid ® capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. “Our launch of Reddy-Lenalidomide...
RHEA-AI
negative
08/31/21 2:43 AM
NYSE : RDY
Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market
Dr. Reddy’ s Laboratories Ltd. today announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2. 5 mg, a therapeutic equivalent generic version of Librax ® approved by the U.S. Food and Drug Administration. Reddy’ s: Dr. Reddy’ s Laboratories Ltd. is an integrated pharmaceutical company,...
RHEA-AI
very negative
08/04/21 10:32 AM
NYSE : RDY
Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as “Dr. Reddy’s”), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy’s will sell its U.S. and Canada territory rights for ELYXYB
RHEA-AI
negative